Results 151 to 160 of about 6,154,682 (249)
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Systematic Evaluation of a Mouse Model of Aging-Associated Parkinson's Disease Induced with MPTP and D-Galactose. [PDF]
Liu T +11 more
europepmc +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Vitamin D Deficiency as a Risk Factor for Onset and Recurrence of Sudden Sensorineural Hearing Loss: A Prospective Cohort Study With Age-Specific Analysis. [PDF]
Hui Q +8 more
europepmc +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
Ǧamal Benɛuf d yiwet seg tgejda n umezgun n teqbaylit, ladɣa s tsuqilin d tserwestin i yexdem i tmiga n yimura igraɣlanen yettwasnen, am tmezgunin n Johann Wolfgang von Gothé akked Tawfiq Lḥakim.
Chabha Ben Matouk
doaj
Impact of vitamin D non-reimbursement policy on therapy discontinuation in the general and rheumatic population in the Netherlands: a cross-sectional study. [PDF]
Singh A +7 more
europepmc +1 more source
ФÑзÑоÑеÑапевÑиÑÐ½Ñ Ð¼ÐµÑоди лÑкÑÐ²Ð°Ð½Ð½Ñ Ñ Ð¿Ð°ÑодонÑологÑÑ
С. І. Бойцанюк +2 more
openalex +2 more sources

